Takeda, Merck KGaA Sign Aptamer Development Deals With Archemix
This article was originally published in PharmAsia News
Executive Summary
Archemix has signed separate agreements with Takeda and Merck KGaA to develop therapeutics based on aptamers, the firms announced June 11